Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and
bipolar depressed patients. Major Depression Disorder patients receiving a single infusion …

The pharmacogenomic network responsible for the rapid antidepressant action of ketamine
and concomitant adverse events in patients has been poorly defined. Integrative, multi-scale …

Background Sub-anesthetic ketamine prompts rapid and robust antidepressant response in
60-70% of patients with treatment resistant depression (TRD), however the underlying …

Background The NMDA receptor antagonist ketamine was found to act as a fast-acting
antidepressant. The effects of single treatment were reported to persist for days to weeks …

The mechanism of action underlying ketamine's rapid antidepressant effects in patients with
depression, both suffering from major depressive disorder (MDD) and bipolar disorder (BD) …

A single sub-anesthetic dose of ketamine produces a rapid and sustained antidepressant
response, yet the molecular mechanisms responsible for this remain unclear. Here, we …

Despite the rapid and sustained antidepressant effects of ketamine and its metabolites, their
underlying cellular and molecular mechanisms are not fully understood. Here, we …

ABSTRACT Preclinical Research The emergence of rapid‐acting antidepressants such as
ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine …

Subanesthetic ketamine evokes rapid antidepressant effects in human patients that persist
long past ketamine's chemical half-life of~ 2 h. Ketamine's sustained antidepressant action …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …